Neoplasma · 2019 · 73 citations · 29 references
MedicineCancer BiologyOncologyChemotherapyGynecologic OncologyMolecular OncologyApoptosis In CancerApoptosis ResistanceCancer ProgressionMalignant NeoplasmsOvarian CancerTumor Suppressor GenesCell Cycle Arrest MechanismsG1 Cell-cycle ArrestG1 Phase ArrestMicrorna Function In CancerOvarian Cancer ChemotherapyOvarian Cancer TreatmentProgrammed Cell Death PathwaysProgrammed Cell Death Regulation
Ovarian cancer is the most lethal gynecologic malignancy in women with an increasing number of cases worldwide. Chemoresistance is the main obstacle for ovarian cancer treatment during clinical therapy. Previous studies found that programmed cell death 1 ligand 1 (PD-L1) was associated with chemoresistance of cancer. However, there were little reports about the function of PD-L1 involved in chemoresistance of ovarian cancer. In our study, cisplatin (DDP)-resistant SKOV3 and A2780 ovarian cancer cell lines (SKOV3/DDP and A2780/DDP) were established. We found that the expression of PD-L1 was increased and miR-34a-5p was decreased in DDP-resistant cells. PD-L1 silencing inhibited chemoresistance of DDP-resistant ovarian cancer cells to DDP, as evidenced by decreased proliferation, G1-phase cell cycle arrest and increased apoptosis. Western blot assay showed that in the presence of DDP, PD-L1 silencing decreased multidrug resistance protein 1 and Cyclin D1 protein levels, whereas increased cleaved-caspase-3 and cleaved-PARP protein levels in these cells. Moreover, we demonstrated that miR-34a-5p negatively regulated the expression of PD-L1 by targeting its 3'-untranslated region. The effects of miR-34a-5p mimic on DDP-treated SKOV3/DDP cells were reversed by the overexpression of PD-L1. Moreover, the tumorigenicity of DDP-resistant ovarian cancer cells in nude mice treated with DDP was attenuated by miR-34a-5p in vivo. The combined data indicate that miR-34a-5p/PD-L1 axis regulates DDP chemoresistance of ovarian cancer cells, providing a deeper insight into the treatment for ovarian cancer.
29
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Drug delivery with carbon nanotubes for in vivo cancer treatment
Zhuang Liu, Kai Chen, Corrine R. Davis et al. · PubMed · 2008 · 2.3K citations · Full text
Pharmacy, Oncology, Pharmacology +17
MicroRNA Signatures in Human Ovarian Cancer
Marilena V. Iorio, Rosa Visone, Gianpiero Di Leva et al. · Cancer Research · 2007 · 1.4K citations · Full text